Search Results for: superoxide dismutase 1

October 17, 2019October 17, 2019

First ALS Patient Enrolled in Phase 1 Trial of AP-101, AL-S Pharma AG Announces

News

AL-S Pharma AG, a biotech company jointly founded and financed by Neurimmune and TVM Capital Life Science, has enrolled the first patient in its Phase 1 clinical trial assessing ... Read more

August 9, 2019August 9, 2019

Complete Loss of SOD1 Function Leads to Severe Motor Problems, Study Says in Warning to Researchers

News

Mutations causing a complete loss of function of the SOD1 gene lead to severe motor problems, a case study reports, calling for caution in research into silencing this gene as ... Read more

July 30, 2019July 30, 2019

FDA Names APB-102, Potential Gene Therapy for Familial ALS, an Orphan Drug

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Apic Bio‘s APB-102, an investigational gene therapy aiming to treat familial amyotrophic lateral sclerosis (ALS) associated with ... Read more

June 4, 2019June 4, 2019

SOD1 Enzyme Clumps May Expose Cells to DNA Damage in Some ALS Patients, Study Suggests

News

The enzyme superoxide dismutase 1 (SOD1) forms clumps inside the cells of some people with sporadic amyotrophic lateral sclerosis (ALS), making them more vulnerable to DNA damage — which ... Read more

May 13, 2019May 13, 2019

Investigational ALS Treatment NPT520-34 Begins Phase 1 Trial in Healthy Volunteers

News

NPT520-34, an investigational small molecule for the treatment of Parkinson’s disease and amyotrophic lateral sclerosis (ALS), is being tested on healthy individuals in a new Phase 1 clinical trial, its developer ... Read more

January 14, 2019January 14, 2019

Human-derived Antibody Against SOD1 Aggregates Improves ALS Symptoms in Mouse Model, Study Shows

News

A human-derived antibody that specifically binds to abnormal superoxide dismutase 1 (SOD1) improved the symptoms and delayed disease progression in a mouse model for amyotrophic lateral sclerosis (ALS), a study ... Read more

November 30, 2018November 30, 2018

Gene Therapy Holds Promise to Treat ALS Caused by SOD1 Mutations, Preclinical Study Shows

News

An experimental gene therapy based on RNA interference (RNAi) shows potential to treat patients with familial amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) ... Read more

November 14, 2018

Gene Therapy That Lowered SOD1 Protein in Primates Could Be Effective in ALS, Study Suggests

News

A gene therapy effectively and safely lowered the production of a key amyotrophic lateral sclerosis (ALS) protein called superoxide dismutase 1 (SOD1) in primates, according to a new study. ... Read more

October 18, 2018October 18, 2018

Voyager Therapeutics Announces Promising Animal Study Data of VY-SOD102 for ALS

News

Voyager Therapeutics’ experimental therapy VY-SOD102 shows promise for treating patients with familial amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene, according to results ... Read more

September 24, 2018September 24, 2018

Misfolded SOD1 Protein May Have Key Role in Sporadic ALS, Study Suggests

News

Specific patterns of a misfolded protein — superoxide dismutase 1 (SOD1) — are found in the brain and spinal cord of patients with sporadic amyotrophic lateral sclerosis (ALS), according to ... Read more

Pin It on Pinterest